Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

Highlights • This is the largest study reporting on leptomeningeal metastasis (LM) in EGFR -mutated NSCLC-patients. • Median survival of EGFR -mutated NSCLC-patients with LM was 3.1 months. • Survival after LM-diagnosis in EGFR -mutated NSCLC-patients with LM may not be superior compared to existing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-09, Vol.89 (3), p.255-261
Hauptverfasser:	Kuiper, Justine L, Hendriks, Lizza E, van der Wekken, Anthonie J, de Langen, Adrianus J, Bahce, Idris, Thunnissen, Erik, Heideman, Daniëlle A.M, Berk, Yvonne, Buijs, Ed J.M, Speel, Ernst-Jan M, Krouwels, Frans H, Smit, Hans J.M, Groen, Harry J.M, Dingemans, Anne-Marie C, Smit, Egbert F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Cohort Studies Combined Modality Therapy EGFR Female Hematology, Oncology and Palliative Medicine Humans Leptomeningeal metastasis Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Meningeal Neoplasms - diagnosis Meningeal Neoplasms - secondary Meningeal Neoplasms - therapy Middle Aged Mutation Neoplasm Staging NSCLC Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Receptor, Epidermal Growth Factor - genetics Retrospective Studies TKI Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • This is the largest study reporting on leptomeningeal metastasis (LM) in EGFR -mutated NSCLC-patients. • Median survival of EGFR -mutated NSCLC-patients with LM was 3.1 months. • Survival after LM-diagnosis in EGFR -mutated NSCLC-patients with LM may not be superior compared to existing data on that in EGFR -wild type NSCLC patients. • Six- and 12-month survival rates were 43.8% and 18.8%, respectively.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.05.023